- Home
- YSXT vs LUNG Comparison
YSXT vs LUNG Comparison
Compare YSXT & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YSXT | LUNG |
|---|---|---|
| Founded | 2011 | 1995 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Automotive Aftermarket | Industrial Specialties |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.8M | 72.2M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | YSXT | LUNG |
|---|---|---|
| Price | $1.39 | $1.83 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $5.38 |
| AVG Volume (30 Days) | 358.7K | ★ 645.4K |
| Earning Date | 01-01-0001 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $83,789,000.00 |
| Revenue This Year | N/A | $6.20 |
| Revenue Next Year | N/A | $21.61 |
| P/E Ratio | $5.57 | ★ N/A |
| Revenue Growth | N/A | ★ 22.01 |
| 52 Week Low | $1.03 | $1.31 |
| 52 Week High | $9.90 | $8.10 |
Technical Indicators
Market Signals| Indicator | YSXT | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 63.25 | 57.62 |
| Support Level | $1.13 | $1.44 |
| Resistance Level | $1.47 | $1.93 |
| Average True Range (ATR) | 0.09 | 0.16 |
| MACD | 0.04 | 0.06 |
| Stochastic Oscillator | 78.38 | 56.00 |
Price Performance
Historical ComparisonAbout YSXT YSX Tech. Co. Ltd Class A Ordinary Shares
YSX Tech Co Ltd provide business solutions to enterprise customers, mainly insurance companies and brokerages, in China. The company has three operating segments: Auto Insurance Aftermarket Value-added Services, Other Scenario-based Customized Services and Software Development and Information Technology Services. Key revenue is generated from Auto Insurance Aftermarket Value-added Services segment which include four types value added services: vehicle safety inspection and check services, vehicle driving risk screening services, designated driver and rescue services and vehicle maintenance and other value-added services.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.